Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms

Physiological Reviews

Volumn 75, Issue 4, 1995, Pages 725-748

  Beavo, Joseph A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ALDOSTERONE; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ATRIAL NATRIURETIC FACTOR; CALCIUM; CALCIUM CHANNEL; CALMODULIN; CATECHOLAMINE; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ENOXIMONE; INSULIN; ISOENZYME; LINSIDOMINE; MESSENGER RNA; NOOTROPIC AGENT; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; TRANSDUCIN; VINPOCETINE; ZINC;

ALTERNATIVE RNA SPLICING; ARTICLE; BLOOD PRESSURE REGULATION; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL TRIAL; DIABETES INSIPIDUS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBUNIT; HEART FUNCTION; HUMAN; MOLECULAR INTERACTION; MULTIGENE FAMILY; NONHUMAN; PLASTICITY; PRIORITY JOURNAL; RETINA DISEASE; SMELLING; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; TRANSCRIPTION REGULATION; VISION;

EID: 0028802726     PISSN: 00319333     EISSN: None     Source Type: Journal    
DOI: 10.1152/physrev.1995.75.4.725     Document Type: Article

References (179)

1. AHN, H. S., M. FOSTER, C. FOSTER, E. SYBERTZ, AND J. N. WELLS. Evidence for essential histidine and cysteine residues in calcium/calmodulin-sensitive cyclic nucleotide phosphodiesterase. Biochemistry 30: 6754-6760, 1991.
2. ALLAN, G., D. CAMBRIDGE, M. J. FOLLENFANT, D. STONE, AND M. V. WHITING. A comparative study of the cardiovascular and biochemical actions of the imidazo[4,5b]pyridine sulmazole and an imidazo[4,5c]pyridine analogue, BW A746C. Br. J. Pharmacol. 93: 387-398, 1988.
3. ALVAREZ, R., G. L. BANERJEE, J. J. BRUNO, G. L. JONES, K. LITTSCHWAGER, A. M. STROSBERG, AND M. C. VENUTI. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties. Mol. Pharmacol. 29: 554-560, 1986.
4. ANGLESON, J. K., AND T. G. WENSEL. A GTPase-accelerating factor for transducin, distinct from its effector cGMP phosphodiesterase, in rod outer segment membranes. Neuron 11: 939-949, 1993.
5. ANGLESON, J. K., AND T. G. WENSEL. Enhancement of rod outer segment GTPase accelerating protein activity by the inhibitory subunit of cGMP phosphodiesterase. J. Biol. Chem. 269: 16290-16296, 1994.
6. BEAVO, J., AND M. D. HOUSLAY (Editors). Cyclic nucleotide phosphodiesterases; structure, function, regulation, and drug action. In: Molecular Pharmacology of Cell Regulation (1st ed.). Chichester, UK: Wiley, 1990, vol. 2, p. 344.
7. BEAVO, J. A. Multiple phosphodiesterase isoenzymes: background, nomenclature, and implications. In: Cyclic Nucleotide Phosphodiesterases: Structure, Regulation, and Drug Action, edited by J. Beavo and M. D. Houslay. Chichester, UK: Wiley, 1990, p. 3-19.
8. BEAVO, J. A., M. CONTI, AND R. J. HEASLIP. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46: 399-405, 1994.
9. BEAVO, J. A., J. G. HARDMAN, AND E. W. SUTHERLAND. Hydrolysis of cyclic guanosine and adenosine 3′,5′-monophosphates by rat and bovine tissues. J. Biol. Chem. 245: 5649-5655, 1970.
10. BEAVO, J. A., N. L. ROGERS, O. B. CROFFORD, J. G. HARDMAN, E. W. SUTHERLAND, AND E. V. NEWMAN. Effects of xanthine derivatives on lipolysis and on adenosine-3′,5′-monophosphate phosphodiesterase activity. Mol. Pharmacol. 6: 597-603, 1970.
11. m, hormone-sensitive phosphodiesterase. Methods Enzymol. 159: 531-40, 1988.
12. BELTMAN, J., D. E. BECKER, E. BUTT, G. S. JENSEN, S. RYBALKIN, B. JASTORFF, AND J. A. BEAVO. Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: the topology of the catalytic domain. Mol. Pharmacol. 47: 330-339, 1995.
13. BENTLEY, J. K, A. KADLECEK, C. H. SHERBERT, D. SEGER, W. K. SONNENBURG, H. CHARBONNEAU, J. P. NOVACK, AND J. A. BEAVO. Molecular cloning of cDNA encoding a "63"-kDa calmodulin-stimulated phosphodiesterase from bovine brain. J. Biol. Chem. 267: 18676-18682, 1992.
14. BLOOM, T. J. AND J. A. BEAVO. Identification of type VII PDE in HUT78 T-lymphocyte cells (Abstract). FASEB J. 8: A372, 1994.
15. BOBON, D., M. BREULET, M. A. GERARD-VANDENHOVE, F. GUIOT-GOFFIOUL, G. PLOMTEUX, M. SASTRE-Y-HERNANDEZ, M. SCHRATZER, B. TROISFONTAINES, R. VON FRENCKELL, AND H. WACHTEL. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur. Arch. Psychiatry Neurol. Sci. 238: 2-6, 1988.
16. BOEHM, M., I. MORANO, B. PIESKE, J. C. RUEEGG, M. WANKERL, R. ZIMMERMANN, AND E. ERDMANN. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ. Res. 68: 689-701, 1991.
17. BORISY, F. F., P. N. HWANG, G. V. RONNETT, AND S. H. SNYDER. High-affinity cAMP phosphodiesterase and adenosine localized in sensory organs. Brain Res. 610: 199-207, 1993.
18. BORISY, F. F., G. V. RONNETT, A. M. CUNNINGHAM, D. JUILFS, J. BEAVO, AND S. H. SNYDER. Calcium/calmodulin-activated phosphodiesterase expressed in olfactory receptor neurons. J. Neurosci. 12: 915-923, 1992.
19. BOWES, C., T. LI, M. DANCIGER, L. C. BAXTER, M. L. APPLEBURY, AND D. B. FARBER. Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase see comments. Nature Lond. 347: 677-680, 1990.
20. BOWES, C., T. LI, W. N. FRANKEL, M. DANCIGER, J. M. COFFIN, M. L. APPLEBURY, AND D. B. FARBER. Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase. Proc. Natl. Acad. Sci. USA 90: 2955-2959, 1993.
21. BRANER, D. A., J. R. FINEMAN, R. CHANG, AND S. J. SOIFER. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol. 264 (Heart Circ. Physiol. 33): H252-H258, 1993.
22. BREER, H. Odor recognition and second messenger signaling in olfactory receptor neurons. Semin. Cell Biol. 5: 25-32, 1994.
23. BREER, H., I. BOEKHOFF, AND E. TAREILUS. Rapid kinetics of second messenger formation in olfactory transduction. Nature Lond. 345: 65-68, 1990.
24. BURNS, F., AND N. J. PYNE. Interaction of the catalytic subunit of protein kinase A with the lung type V cyclic GMP phosphodiesterase: modulation of non-catalytic binding sites. Biochem. Biophys. Res. Commun. 189: 1389-1396, 1992.
25. BURNS, F., I. W. RODGER, AND N. J. PYNE. The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-speciflc phosphodiesterase from guinea-pig lung. Biochem. J. 283: 487-491, 1992.
26. BUTCHER, R. W., AND E. W. SUTHERLAND Adenosine 3′,5′-phosphate in biological materials. J. Biol. Chem. 237: 1244-1250, 1962.
27. CAMPBELL, R. K. Clinical update on pentoxifylline therapy for diabetes-induced peripheral vascular disease. Ann. Pharmacother. 27: 1099-1105, 1993.
28. CHAN, S. C., AND J. M. HANIFIN. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J. Lab. Clin. Med. 121: 44-51, 1993.
29. CHARBONNEAU, H. Structure-function relationships among cyclic nucleotide phosphodiesterases. In: Cyclic Nucleotide Phosphodiesterases: Structure, Function, Regulation, and Drug Action, edited by J. Beavo and M. D. Houslay. Chichester, UK: Wiley, 1990, p. 267-298.
30. CHARBONNEAU, H., N. BEIER, K. A. WALSH, AND J. A. BEAVO. Identification of a conserved domain among cyclic nucleotide phosphodiesterases from diverse species. Proc. Natl. Acad. Sci. USA 83: 9308-9312, 1986.
31. CHARBONNEAU, H., S. KUMAR, J. P. NOVACK, D. K. BLUMENTHAL, P. R. GRIFFIN, J. SHABANOWITZ, D. F. HUNT, J. A. BEAVO, AND K. A. WALSH. Evidence for domain organization within the 61-kDa calmodulin-dependent cyclic nucleotide phosphodiesterase from bovine brain. Biochemistry 30: 7931-7940, 1991.
32. CHEUNG, W. Y. Cyclic nucleotide 3′,5′-nucleotide phosphodiesterase: evidence for and properties of a protein activator. Biochem. Biophys. Res. Commun. 38: 533-538, 1970.
33. CHOI, E. J., Z. XIA, AND D. R. STORM. Stimulation of the type III olfactory adenylyl cyclase by calcium and calmodulin. Biochemistry 31: 6492-6498, 1992.
34. CHOI, E. J., Z. XIA, E. C. VILLACRES, AND D. R. STORM. The regulatory diversity of adenylyl cyclases. Curr. Opin. Cell Biol. 5: 269-273, 1993.
35. CLARKE, W. R., S. UEZONO, A. CHAMBERS, AND P. DOEPFNER. The type-III phosphodiesterase inhibitor milrinone and type-V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm. Pharmacol. 7: 81-89, 1994.
36. COATES, W. J., B. CONNOLLY, D. DHANAK, S. T. FLYNN, AND A. WORBY. Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. J. Med. Chem. 36: 1387-1392, 1993.
37. COLUCCI, W. S., E. H. SONNENBLICK, K F. ADAMS, M. BERK, S. C. BROZENA, A. J. COWLEY, J. M. GRABICKI, AND S. A. KUBO. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators. J. Am. Coll. Cardiol. 22, Suppl. A: 113A-118A, 1993.
38. CONTI, M., G. NEMOZ, C. SETTE, AND E. VICINI. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. 16: 370-388, 1995.
39. CORTIJO, J., J. BOU, J. BELETA, I. CARDEL'US, J. LLENAS, E. MORCILLO, AND R. W. GRISTWOOD. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br. J. Pharmacol. 108: 562-568, 1993.
40. COTE, R. H., M. D. BOWNDS, AND V. Y. ARSHAVSKY. cGMP binding sites on photoreceptor phosphodiesterase: role in feedback regulation of visual transduction. Proc. Natl. Acad. Sci. USA 91: 4845-4849, 1994.
41. DELANGE, R. J., R. G. KEMP, W. D. RILEY, R. A. COOPER, AND E. G. KREBS. Activation of skeletal muscle phosphorylase kinase by adenosine triphosphate and adenosine 3′,5′-monophosphate. J. Biol. Chem. 243: 2200-2208, 1968.
42. DETERRE, P., J. BIGAY, F. FORQUET, M. ROBERT, AND M. CHABRE. cGMP phosphodiesterase of retinal rods is regulated by two inhibitory subunits. Proc. Natl. Acad. Sci. USA 85: 2424-2428, 1988.
43. DUBOIS-RANDE, J. L., C. GUEROT, F. JAN, M. BROCHIER, A. SACREZ, A. VACHERON, H. LAMBERT, M. BORY, Y. LE BLOCH, AND B. CHAVANCE. Efficacy of intravenous milrinone in the treatment of acute congestive cardiac failure. Results of a French multicenter study. Ann. Cardiol. Angiol. Paris 42: 105-114, 1993.
44. ELLIOTT, K. R., J. L. BERRY, A. J. BATE, R. W. FOSTER, AND R. C. SMALL. The isoenzyme selectivity of AH 21-132 as an inhibitor of cyclic nucleotide phosphodiesterase activity. J. Enzyme Inhib. 4: 245-251, 1991.
45. ERNEUX, C., S. J. VAN, F. MIOT, P. COCHAUX, C. DECOSTER, AND J. E. DUMONT. A mechanism in the control of intracellular cAMP level: the activation of a calmodulin-sensitive phosphodiesterase by a rise of intracellular free calcium. Mol. Cell. Endocrinol. 43: 123-134, 1985.
46. ERNST, E. Pentoxifylline for intermittent claudication. A critical review. Angiology 45: 339-345, 1994.
47. FARBER, D. B., J. S. DANCIGER, AND G. AGUIRRE. The beta subunit of cyclic GMP phosphodiesterase mRNA is deficient in canine rod-cone dysplasia 1. Neuron 9: 349-356, 1992.
48. FELDMAN, A. M., M. R. BRISTOW, W. W. PARMLEY, P. E. CARSON, C. J. PEPINE, E. M. GILBERT, J. E. STROBECK, AND G. H. HENDRIX. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N. Engl. J. Med. 329: 149-155, 1993.
49. FERRARA, D., A. GOLINO, S. NOTARANGELO, P. STASSANO, G. BRANDO, A. V. DE, E. ESPOSITO, AND N. AVOSSA. Use of enoximone in the postoperative course of heart surgery. Minerva Cardioangiol 41: 147-151, 1993.
50. FISCHMEISTER, R., AND H. C. HARTZELL. Cyclic guanosine 3′,5′-monophosphate regulates the calcium current in single cells from frog ventricle. J. Physiol. Lond. 387: 453-472, 1987.
51. FLEISCHHACKER, W. W., H. HINTERHUBER, H. BAUER, B. PFLUG, P. BERNER, C. SIMHANDL, R. WOLF, AND W. GERLACH. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26: 59-64, 1992.
52. FLORIO, S. K., R. K. PRUSTI, AND J. A. BEAVO. Sequencing, cloning, expression, and localization of the 15 kDa (δ) subunit of retinal phosphodiesterases (Abstract). FASEB J. 8: A372, 1994.
53. FLORIO, V. A., W. K. SONNENBURG, R. JOHNSON, K. S. KWAK, G. S. JENSEN, K. A. WALSH, AND J. A. BEAVO. Phosphorylation of the "61" kDa calmodulin-stimulated cyclic nucleotide phosphodiesterase at serine 120 reduces its affinity for calmodulin. Biochemistry 33: 8948-8954, 1994.
54. FRANCIS, S. H., J. L. COLBRAN, McALLISTER-LUCAS, AND J. D. CORBIN. Cyclic nucleotide phosphodiesterases are zinc hydrolases as indicated by conserved zinc-binding motifs, specific zinc binding, and zinc supported catalysis (Abstract). FASEB J. 8: A371, 1994.
55. FRANCIS, S. H., M. K. THOMAS, AND J. D. CORBIN. Cyclic GMP-binding cyclic GMP-specific phosphodiesterase from lung. In: Cyclic Nucleotide Phosphodiesterases: Structure, Regulation, and Drug Action, edited by J. Beavo and M. D. Houslay. Chichester, UK: Wiley, 1990, p. 117-140.
56. GAL, A., U. ORTH, W. BAEHR, E. SCHWINGER, AND T. ROSENBERG. Heterozygous missense mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal dominant stationary night blindness. Nature Genet. 7: 64-68, 1994.
57. GEREMIA, R., P. ROSSI, D. MOCINI, R. PEZZOTTI, AND M. CONTI. Characterization of a calmodulin-dependent high-affinity cyclic AMP and cyclic GMP phosphodiesterase from male mouse germ cells. Biochem. J. 217: 693-700, 1984.
58. GETTYS, T. W., P. F. BLACKMORE, AND J. D. CORBIN. An assessment of phosphodiesterase activity in situ after treatment of hepatocytes with hormones. Am. J. Physiol. 254 (Endocrinol. Metab. 17): E449-E453, 1988.
59. m phosphodiesterase of adipocytes by addition of cAMP-dependent protein kinase. J. Biol. Chem. 263: 10359-10363, 1988.
60. GILLESPIE, E. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem. Pharmacol. 37: 2866-2868, 1988.
61. GILLESPIE, P. G., AND J. A. BEAVO. Characterization of a bovine cone photoreceptor phosphodiesterase purified by cyclic GMP-sepharose chromatography. J. Biol. Chem. 263: 8133-8141, 1988.
62. GILLESPIE, P. G., AND J. A. BEAVO. Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948. Mol. Pharmacol. 36: 773-781, 1989.
63. GILLESPIE, P. G., R. K. PRUSTI, E. D. APEL, AND J. A. BEAVO. A soluble form of bovine rod photoreceptor phosphodiesterase has a novel 15-kDa subunit. J. Biol. Chem. 264: 12187-12193, 1989.
64. GRANT, P. G., AND R. W. COLMAN. Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. Biochemistry 23: 1801-1807, 1984.
65. GROPPI, V. E., F. STEINBERG, H. R. KASLOW, N. WALKER, AND H. R. BOURNE. Identification by direct photoaffinity labeling of an altered phosphodiesterase in a mutant S49 lymphoma cell. J. Biol. Chem. 258: 9717-9723, 1983.
66. HAGIWARA, M., T. ENDO, AND H. HIDAKA. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol. 33: 453-457, 1984.
67. HAMMERSCHMIDT, D. E., D. KOTASEK, T. MCCARTHY, P. W. HUH, G. FREYBURGER, AND G. M. VERCELLOTTI. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J. Lab. Clin. Med. 112: 254-263, 1988.
68. HANSEN, R. S., AND J. A. BEAVO. Purification of two calcium/ calmodulin dependent forms of cyclic nucleotide phosphodiesterase by using conformation-specific monoclonal antibody chromatography. Proc. Natl. Acad. Sci. USA 79: 2788-2792, 1982.
69. HARRISON, S. A., D. H. REIFSNYDER, B. GALLIS, G. G. CADD, AND J. A. BEAVO. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol. Pharmacol. 29: 506-514, 1986.
70. 2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 264: 10884-10887, 1989.
71. HAUSDORF, G. Experience with phosphodiesterase inhibitors in paediatric cardiac surgery. Eur. J. Anaesthesiol. Suppl. 8: 25-30, 1993.
72. HIDAKA, H., AND T. ENDO. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase-basic and potential clinical applications. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 16: 245-259, 1984.
73. 2+-dependent modulator protein. J. Biol. Chem. 252: 43-50, 1977.
74. HOMMA, S., S. M. GAPSTUR, A. COFFEY, H. VALTIN, AND T. P. DOUSA. Role of cAMP-phosphodiesterase isozymes in pathogenesis of murine nephrogenic diabetes insipidus. Am. J. Physiol. 261 (Renal Fluid Electrolyte Physiol. 30): F345-F353, 1991.
75. HOUSLAY, M. D., AND E. KILGOUR. Cyclic nucleotide phosphodiesterases in liver: a review of their characterization, regulation by insulin and glucagon, and their role in controlling intracellular cyclic AMP concentrations. In: Cyclic Nucleotide Phosphodieslerases: Structure, Function, Regulation, and Drug Action, edited by J. Beavo and M. D. Houslay. Chichester, UK: Wiley, 1990, p. 185-218.
76. HUTCHISON, A. A. Respiratory disorders of the neonate. Curr. Opin. Pediatr. 6: 142-153, 1994.
77. HYNIE, S., G. KRISHNA, AND B. B. BRODIE. Theophylline as a tool in studies of the role of cyclic adenosine 3′,5′-monophosphate in hormone-induced lipolysis. J. Pharmacol. Exp. Ther. 153: 90-96, 1966.
78. ICHIMURA, M., AND H. KASE. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem. Biophys. Res. Commun. 193: 985-990, 1993.
79. IVERSEN, S., E. MAYER, U. HAKE, W. SCHMIEDT, H. JAKOB, AND H. OELERT. Efficacy of phosphodiesterase inhibitor enoximone in management of postcardiotomy cardiogenic shock. Scand. J. Thorac. Cardiovasc. Surg. 26: 143-149, 1992.
80. JACOBITZ, S., M. M. McLAUGHLIN, G. P. LIVI, M. D. RYAN, AND T. J. TORPHY. The role of conserved histidine residues on cAMP hydrolyzing activity and rolipram binding of human phosphodiesterase IV (Abstract). FASEB J. 8: A371, 1994.
81. m, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain. J. Biol. Chem. 267: 18929-18939, 1992.
82. JOURNOIS, D., P. POUARD, P. MAURIAT, T. MALHERE, P. VOUH'E, AND D. SAFRAN. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J. Thorac. Cardiovasc. Surg. 107: 1129-1135, 1994.
83. KAM, P. C., AND G. GOVENDER. Nitric oxide: basic science and clinical applications. Anaesthesia 49: 515-521, 1994.
84. KARIYA, T., AND L. J. A. D. R. C. WILLE. Biochemical studies on the mechanism of cardiotonic activity of MDL 17043. J. Cardiovasc. Pharmacol. 4: 509-514, 1982.
85. KAUFFMAN, R. F., V. G. CROWE, B. G. UTTERBACK, AND D. W. ROBERTSON. LY 195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol. Pharmacol. 30: 609-616, 1987.
86. 3H]LY186126, a cardiotonic phosphodiesterase inhibitor, in canine cardiac membranes. Circ. Res. 65: 154-163, 1989.
87. KINCAID, R. L, C. D. BALABAN, AND M. L. BILLINGSLEY. Regional and developmental expression of calmodulin-dependent cyclic nucleotide phosphodiesterase in rat brain. Adv. Second Messenger Phosphoprotein Res. 25: 111-122, 1992.
88. KIRSTEIN, M., M. RIVET-BASTIDE, A. BERNARDEAU, S. HATEM, J. MERCADIER, AND R. FISCHMEISTER. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J. Clin. Invest. In press.
89. KUKOVETZ, W. R., AND G. POCH. Inhibition of cyclic-3′,5′-nucleotide phosphodiesterase as a possible mode of action of papaverine and similarly acting drugs. Naunyn-Schmiederbergs Arch. Pharmacol 267: 189-194, 1970.
90. LAGNADO, L., AND D. BAYLOR. Signal flow in visual transduction. Neuron 8: 995-1002, 1992.
91. 2+-sensitive phosphodiesterase purified from bovine heart. Biochemistry 18: 2820-2824, 1979.
92. LECHNER, A. J., L. R. ROUBEN, L. H. POTTHOFF, T. L. TREDWAY, AND G. M. MATUSCHAK. Effects of pentoxifylline on tumor necrosis factor production and survival during lethal E. coli sepsis vs. disseminated candidiasis with fungal septic shock. Circ. Shock 39: 306-315, 1993.
93. LEE, M. A., R. J. WEST, AND J. MOSS. Atrial natriuretic factor reduces cyclic adenosine monophosphate content of human fibroblasts by enhancing phosphodiesterase activity. J. Clin. Invest. 82: 388-393, 1988.
94. LEPPO, J. A. Dipyridamole myocardial perfusion imaging. J. Nucl. Med. 35: 730-733, 1994.
95. LI, T. S., K. VOLPP, AND M. L. APPLEBURY. Bovine cone photoreceptor cGMP phosphodiesterase structure deduced from a cDNA clone. Proc. Natl. Acad. Sci. USA 87: 293-297, 1990.
96. L'OPEZ, A. P., A. RASC'ON, V. C. MANGANIELLO, K. E. ANDERSSON, P. BELFRAGE, AND E. DEGERMAN. Insulin induced phosphorylation and activation of the cGMP-inhibited cAMP phosphodiesterase in human platelets. Biochem. Biophys. Res. Commun. 186: 517-523, 1992.
97. LOPEZ-APARICIO, P., A. ROSCON, V. C. MANGANIELLO, K-E. ANDERSSON, P. BELFRAGE, AND E. DEGERMAN. Insulin induced phosphorylation and activation of the cGMP-inhibited phosphodiesterase in human platelets. Biochem. Biophys. Res. Commun. 186: 517-523, 1992.
98. LOTEN, E. G., AND J. G. T. SNYED. An effect of insulin on adipose tissue phosphodiesterase. Biochem. J. 120: 187-193, 1970.
99. LOUGHNEY, K., T. MARTINS, B. SONNENBURG, J. BEAVO, AND K. FERGUSON. Isolation and characterization of cDNAs corresponding to two human calmodulin stimulated 3′,5′ cyclic nucleotide phosphodiesterase genes (Abstract). FASEB J. 8: A469, 1994.
100. LOWENTHAL, A., AND M. BUYSE. Secondary prevention of stroke: does dipyridamole add to aspirin? Acta Neurol. Belg. 94: 24-34, 1994.
101. LUDVIG, N., V. BURMEISTER, P. C. JOBE, AND R. L. KINCAID. Electron microscopic immunocytochemical evidence that the calmodulin-dependent cyclic nucleotide phosphodiesterase is localized predominantly at postsynaptic sites in the rat brain. Neuroscience 44: 491-500, 1991.
102. MACFARLAND, R. T., B. D. ZELUS, AND J. A. BEAVO. High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J. Biol. Chem. 266: 136-142, 1991.
103. m cAMP phosphodiesterase: probable target for anti-thrombotic agents. Proc. Natl. Acad. Sci. USA 83: 6660-6663, 1986.
104. m: cAMP phosphodiesterase found in human platelets. J. Cyclic Nucleotide Protein Phosphorylation Res. 11: 487-496, 1988.
105. MACPHEE, C. H., D. H. REIFSNYDER, T. A. MOORE, K. M. LEREA, AND J. A. BEAVO. Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. J. Biol. Chem. 263: 10353-10358, 1988.
106. MANGANIELLO, V. C., C. J. SMITH, E. DEGERMAN, V. VASTA, H. TORNQVIST, AND P. BELFRAGE. Molecular mechanisms involved in the antihpolytic action of insulin: phosphorylation and activation of a particulate adipocyte cAMP phosphodiesterase. Adv. Exp. Med. Biol. 293: 239-248, 1991.
107. MARTINS, T. J., M. C. MUMBY, AND J. A. BEAVO. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J. Biol. Chem. 257: 1973-1979, 1982.
108. MASUOKA, H., M. ITO, M. SUGIOKA, H. KOZEH, T. KONISHI, T. TANAKA, AND T. NAKANO. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent. Biochem. Biophys. Res. Commun. 190: 412-417, 1993.
109. MAURICE, D. H., AND R. J. HASLAM. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol. 37: 671-681, 1990.
110. McALLISTER, L. L. M., W. K. SONNENBURG, A. KADLECEK, D. SEGER, H. L. TRONG, J. L. COLBRAN, M. K. THOMAS, AND K. A. WALSH. The structure of a bovine lung cGMP-binding, cGMP-speciflc phosphodiesterase deduced from a cDNA clone. J. Biol. Chem. 268: 22863-22873, 1993.
111. MEACCI, E., M. TAIRA, M. J. MOOS, C. J. SMITH, M. A. MOVSESIAN, E. DEGERMAN, P. BELFRAGE, AND V. MANGANIELLO. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc. Natl. Acad. Sci. USA 89: 3721-3725, 1992.
112. MERY, P. F, AND R. FISCHMEISTER. EHNA reverses the inhibitory effect of cGMP on cardiac L-type Ca current via PDE-II inhibition (Abstract). FASEB J. 8: A82, 1994.
113. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc. Natl. Acad. Sci. USA 88: 1197-1201, 1991.
114. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J. Biol Chem. 268: 26286-26295, 1993.
115. MESKINI, N., G. NEMOZ, I. OKYAYUZBAKLOUTI, M. LAGARDE, AND A. F. PRIGENT. Phosphodiesterase inhibitory profile of some related xanthlne derivatives pharmacologically active on the peripheral microcirculation. Biochem. Pharmacol. 47: 781-788, 1994.
116. MICHAELI, T., T. J. BLOOM, T. MARTINS, K. LOUGHNEY, K. FERGUSON, M. RIGGS, L. RODGERS, AND J. A. BEAVO. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J. Biol. Chem. 268: 12925-12932, 1993.
117. MOORE, J. J., D. W. COMBS, AND A. J. TOBIA. Bemoradan - a novel inhibitor of the rolipram-insensitive cyclic AMP phosphodiesterase from canine heart tissue. Biochem. Pharmacol. 42: 679-683, 1991.
118. MURRAY, K. J., R. J. EDEN, J. S. DOLAN, D. C. GRIMSDITCH, C. A. STUTCHBURY, B. PATEL, A. KNOWLES, AND A. WORBY. The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function. Br. J. Pharmacol. 107: 463-470, 1992.
119. 2+ and calmodulin-dependent cyclic-nucleotide phosphodiesterase from Streptomyces argenteolus. J. Antibiot. Tokyo 45: 341-347, 1992.
120. NEMECEK, G. M., AND T. W. HONEYMAN. The role of cyclic nucleotide phosphodiesterase in the inhibition of cyclic AMP accumulation by carbachol and phosphatidate. J. Cyclic Nucleotide Res. 8: 395-408, 1982.
121. NEWSHOLME, S. J., AND L. SCHWARTZ. cAMP-speciflc phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva. Inflammation 17: 25-31, 1993.
122. NICHOLSON, C. D., S. A. JACKMAN, AND R. WILKE. The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site. Br. J. Pharmacol. 97: 889-897, 1989.
123. NIKI, T., AND H. MORI. Phase I study of cilostazol. Safety evaluation at increasing single doses in healthy volunteers. Arzneimittelforschung 35: 1173-1185, 1985.
124. NONY, P., J. P. BOISSEL, M. LIEVRE, A. LEIZOROVICZ, M. C. HAUGH, S. FAREH, AND B. DEBREYNE. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients - a meta-analysis. Eur. J. Clin. Pharmacol. 46: 191-196, 1994.
125. NOVACK, J. P., H. CHARBONNEAU, J. K. BENTLEY, K. A. WALSH, AND J. A. BEAVO. Sequence comparison of the 63-, 61-, and 59-kDa calmodulin-dependent cyclic nucleotide phosphodiesterases. Biochemistry 30: 7940-7947, 1991.
126. PACKER, M., J. R. CARVER, R. J. RODEHEFFER, R. J. IVANHOE, R. DIBIANCO, S. M. ZELDIS, G. H. HENDRIX, AND W. J. BOMMER. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325: 1468-1475, 1991.
127. PARSONS, W. J., V. RAMKUMAR, AND G. L. STILES. The new cardiotonic agent sulmazole is an Al1adenosine receptor antagonist and functionally blocks the inhibitory regulator, G,. Mol. Pharmacol. 33: 441-448, 1988.
128. PITTLER, S. J., AND W. BAEHR. Identification of a nonsense mutation in the rod photoreceptor cGMP phosphodlesterase beta-sub- unit gene of the rd mouse. Proc. Natl. Acad. Sci. USA 88: 8322-8326, 1991.
129. POLLI, J. W., AND R. L. KINCAID. Expression of a calmodulindependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J. Neurosci. 14: 1251-1261, 1994.
130. QIN, N., S. J. PITTLER, AND W. BAEHR. In vitro isoprenylation and membrane association of mouse rod photoreceptor cGMP phosphodiesterase alpha and beta subunits expressed in bacteria. J. Biol. Chem. 267: 8458-8463, 1992.
131. RASCON, A., E. DEGERMAN, M. TAIRA, E. MEACCI, C. J. SMITH, V. MANGANIELLO, P. BELFRAGE, AND H. TORNQVIST. Identification of the phosphorylation site in vitro for cAMP-dependent protein kinase on the rat adipocyte cGMP-inhibited cAMP phosphodiesterase. J. Biol. Chem. 269: 11962-11966, 1994.
132. REEVES, M. L., AND P. J. ENGLAND. Cardiac phosphodiesterases and the functional effects of selective inhibition. In: Cyclic Nucleotide Phosphodiesterases: Structure, Regulation, and Drug Action, edited by J. A. Beavo and M. D. Houslay. Chichester, UK: Wiley, 1990, p. 299-316.
133. REPASKE, D. R., J. G. CORBIN, M. CONTI, AND M. F. GOY. A cyclic GMP-stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain. Neuroscience 56: 673-686, 1993.
134. ROBERTS, P. J., K. L. YONG, A. KHWAJA, B. V. JOHNSON, A. R. PIZZEY, J. E. CARVER, I. E. ADDISON, AND D. C. LINCH. Pentoxifylline at clinically achievable levels inhibits FMLP-induced neutrophil responses, but not priming, upregulation of cell-adhesion molecules, or migration induced by GM-CSF. Eur. J. Haematol. 50: 1-10, 1993.
135. RUPPERT, D., AND K. U. WEITHMAN. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro. Life Sci. 31: 2037-2043, 1982.
136. SAMLASKA, C. P., AND E. A. WINFIELD. Pentoxifylline. J. Am. Acad. Dermatol. 30: 603-621, 1994.
137. SCHNEIDER, H. H., R. SCHMIECHEN, M. BREZINSH, AND J. SEIDLER. Stereospecific binding of the antidepressant rolipram to brain specific structures. Eur. J. Pharmacol. 127: 105-115, 1986.
138. SCHUDT, C., S. WINDER, M. ELTZE, U. HLIAN, AND R. BEUME. Zardaverine: a cyclic AMP specific PDE III/TV inhibitor. Agents Actions Suppl. 34: 379-402, 1991.
139. SCOTT, A. I., A. F. PERINI, P. A. SHERING, AND L. J. WHALLEY. In-patient major depression: is rolipram as effective as amitriptyline? Eur. J. Clin. Pharmacol. 40: 127-129, 1991.
140. SETTE, C., E. VICINI, AND M. CONTI. The rat PDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem. 269: 18271-18274, 1994.
141. SHARMA, R. K., A. M. ADACHI, K. ADACHI, AND J. H. WANG. Demonstration of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by monoclonal antibodies. J. Biol. Chem. 259: 9248-9254, 1984.
142. SHARMA, R. K., AND J. H. WANG. Differential regulation of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isoenzymes by cyclic AMP-dependent protein kinase and calmodulin-dependent phosphatase. Proc. Natl. Acad. Sci. USA 82: 2603-2607, 1985.
143. SHARMA, R. K., AND J. H. WANG. Purification and characterization of bovine lung calmodulin-dependent cyclic nucleotide phosphodiesterase. An enzyme containing calmodulin as a subunit. J. Biol. Chem. 261: 14160-14166, 1986.
144. 2+-calmodulin-stimulated cyclic GMP phosphodiesterase from bovine brain. Biochemistry 24: 672-678, 1985.
145. SHEPPARD, H., AND G. A. T. W. WIGGAN. Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues. Adv. Cyclic Nucleotide Res. 1: 103-112, 1972.
146. SIRCAR, I., R. E. WEISHAAR, D. KOBYLARZ, W. H. MOOS, AND J. A. BRISTOL. Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity. J. Med. Chem. 30: 1955-1962, 1987.
147. SMITH, C. J., V. VASTA, E. DEGERMAN, P. BELFRAGE, AND V. C. MANGANIELLO. Hormone-sensitive cyclic GMP-inhibited cyclic AMP phosphodiesterase in rat adipocytes. Regulation of insulin-and cAMP-dependent activation by phosphorylation. J. Biol. Chem. 266: 13385-13390, 1991.
148. SMOAKE, J. A., L. S. JOHNSON, AND G. T. PEAKE. Calmodulin-dependent high-affinity cyclic AMP phosphodiesterases in liver membranes. Arch. Biochem. Biophys. 206: 331-335, 1981.
149. SONNENBURG, W. K., D. SEGER, AND J. A. BEAVO. Molecular cloning of a cDNA encoding the "61-kDa" calmodulin-stimulated cyclic nucleotide phosphodiesterase. Tissue-specific expression of structurally related isoforms. J. Biol. Chem. 268: 645-652, 1993.
150. SUBER, M. L., S. J. PITTLER, N. QIN, G. C. WRIGHT, V. HOLCOMBE, R. H. LEE, C. M. CRAFT, AND R. N. LOLLEY. Irish setter dogs affected with rod/cone dysplasia contain a nonsense mutation in the rod cGMP phosphodiesterase beta-subunit gene. Proc. Natl. Acad. Sci. USA 90: 3968-3972, 1993.
151. SWINNEN, J. V., D. R. JOSEPH, AND M. CONTI. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proc. Natl. Acad. Sci. USA 86: 8197-8201, 1989.
152. SWINNEN, J. V., K. E. TSIKALAS, AND M. CONTI. Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. J. Biol. Chem. 266: 18370-18377, 1991.
153. TAIRA, M., S. C. HOCKMAN, J. C. CALVO, M. TAIRA, P. BELFRAGE, AND V. C. MANGANIELLO. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J. Biol. Chem. 268: 18573-18579, 1993.
154. TANNER, L. I., T. K. HARDEN, J. N. WELLS, AND M. W. MARTIN. Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of I32INI human astrocytoma cells. Mol. Pharmacol. 29: 455-460, 1986.
155. TEIXEIRA, M. M., A. G. ROSSI, T. J. WILLIAMS, AND P. G. HELLEWELL. Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br. J. Pharmacol. 112: 332-340, 1994.
156. THOMAS, M. K., S. H. FRANCIS, S. J. BEEBE, T. W. GETTYS, AND J. D. CORBIN. Partial mapping of cyclic nucleotide sites and studies of regulatory mechanisms of phosphodiesterases using cyclic nucleotide analogues. Adv. Second Messenger Phosphoprotein Res. 25: 45-53, 1992.
157. THOMAS, M. K., S. H. FRANCIS, AND J. D. CORBIN. Substrateand kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J. Biol. Chem. 265: 14971-14978, 1990.
158. THOMPSON, W. J., AND M. M. APPLEMAN. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10: 311-316, 1971.
159. TORPHY, T. J., AND L. B. CIESLINSKI. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol. Pharmacol. 37: 206-214, 1990.
160. TORPHY, T. J., W. E. J. DEWOLF, D. W. GREEN, AND G. P. LIVI. Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents Actions Suppl. 43: 51-71, 1993.
161. TORPHY, T. J., G. P. LIVI, J. M. BALCAREK, J. R. WHITE, F. H. CHILTON, AND B. J. UNDEM. Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma. Adv. Second Messenger Phosphoprotein Res. 25: 289-305, 1992.
162. TOURNAYE, H., R. JANSSENS, P. DEVROEY, AND A. VANSTEIRTEGHEM. The influence of pentoxifylline on motility and viability of spermatozoa from normozoospermic semen samples. Int. J. Androl. 17: 1-8, 1994.
163. VAN MEEL, J. C., R. ZIMMERMANN, W. DIEDEREN, E. ERDMAN, AND U. MRWA. Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole. Biochem. Pharmacol. 37: 213-220, 1988.
164. m cyclic AMP phosphodiesterase (cGI PDE) in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 183: 1070-1075, 1992.
165. VERNON, M. W., R. C. HEEL, AND R. N. BROGDEN. Enoximone. A review of its pharmacological properties and therapeutic potential. Drugs 42: 997-1017, 1991.
166. WACHTEL, H., AND H. H. SCHNEIDER. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology 25: 1119-1126, 1986.
167. WANG, J. H., R. K. SHARMA, AND M. J. MOOIBROEK. Calmodulin-stimulated cyclic nucleotide phosphodiesterases. In: Cyclic Nucleotide Phosphodiesterases: Structure, Regulation, and Drug Action, edited by J. Beavo and M. D. Houslay. Chichester, UK: Wiley, 1990, p. 19-60.
168. WEISHAAR, R. E., S. D. BURROWS, D. C. KOYLARZ, M. M. QUADE, AND D. B. EVANS. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem. Pharmacol. 35: 787-800, 1986.
169. WEISHAAR, R. E., S. D. KOBYLARZ, J. KEISER, S. J. HALEEN, T. C. MAJOR, S. RAPUNDALO, J. T. PETERSON, AND R. PANEK. Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of atrial natriuretic factor. Hypertension Dallas 15: 528-540, 1990.
170. WELLS, J. N., AND J. R. MILLER. Methylxanthine inhibitors of phosphodiesterases. Methods Enzymol. 159: 489-496, 1988.
171. WHALIN, M. E., J. G. SCAMMELL, S. J. STRADA, AND W. J. THOMPSON. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells. Mol. Pharmacol. 39: 711-717, 1991.
172. WILKINS, M. R., S. L. SETTLE, AND P. NEEDLEMAN. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3′,5′-cyclic monophosphate degradation. J. Clin. Invest. 85: 1274-1279, 1990.
173. WILKINS, M. R., S. L. SETTLE, P. T. STOCKMANN, AND P. NEEDLEMAN. Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc. Natl. Acad. Sci. USA 87: 6465-6469, 1990.
174. YAN, C., AND J. A. BEAVO. Molecular cloning and cellular distribution of the 75 kDa calmodulin-dependent phosphodiesterase (Abstract). FASEB J. 8: A81, 1994.
175. YAN, C., J. K. BENTLEY, W. K. SONNENBURG, AND J. A. BEAVO. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J. Neurosci. 14: 973-984, 1993.
176. YAN, C., A. Z. ZHAO, J. K. BENTLEY, K. LOUGHNEY, K. FERGUSON, AND J. A. BEAVO. A novel calmodulin-dependent phosphodiesterase that may mediate rapid olfactory signal termination. Proc. Natl. Acad. Sci. USA. In press.
177. YANG, Q., M. PASKIND, G. BOLGER, W. J. THOMPSON, D. R. REPASKE, L. S. CUTLER, AND P. M. EPSTEIN. A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem. Biophys. Res. Commun. 205: 1850-1858, 1994.
178. YASUNAGA, K., AND K. MASE. Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease. Arzneimittelforschung 35: 1186-1188, 1985.
179. YASUNAGA, K., AND K. MASE. Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. Arzneimittelforschung 35: 1189-1192, 1985.